Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-02

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and effectiveness of the BlueLeaf System for the restoration of venous competence for the treatment of symptomatic chronic venous insufficiency (CVI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System (INFINITE-Canada)

NCT05047302

Chronic Venous Insufficiency

WITHDRAWN NA

Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System (INFINITE-US)

NCT04225806

Chronic Venous Insufficiency (CVI) Deep Vein Reflux

TERMINATED NA

Non-Invasive Management of Chronic Venous Insufficiency

NCT00950378

Venous Insufficiency

COMPLETED

Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.

NCT06519435

Deep Vein Thrombosis

RECRUITING

Evaluation of Pain Associated With Chronic Venous Insufficiency

NCT04794712

Chronic Venous Insufficiency Varicose Veins of Lower Limb

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, non-randomized, multicenter pre-market feasibility study to evaluate subjects treated with the BlueLeaf System for the treatment of symptomatic CVI of the lower extremity. The BlueLeaf System is designed to form autogenous tissue leaflets from vein walls in the femoral and popliteal veins without the use of a permanent vascular implant for the treatment of CVI. Subjects meeting eligibility criteria will be enrolled and may be followed through 5 years post treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Venous Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

prospective, non-randomized, multicenter pre-market feasibility study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BlueLeaf System

The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.

Group Type EXPERIMENTAL

BlueLeaf System

Intervention Type DEVICE

The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BlueLeaf System

The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptomatic CVI subjects, Clinical Etiological Anatomical Pathophysiological (CEAP) grade 3 to 6;
* Failed compression therapy of at least 6 months' duration;
* Deep system venous reflux characterized by \>1 second reflux time;
* Presence of at least one target site within the target vessel.

Exclusion Criteria

* Untreated significant superficial venous incompetence which, in the opinion of the Investigator, may be the primary source of existing symptoms;
* Deep venous intervention in the target limb or outflow vessels within 6 months of consent;
* Significant peripheral arterial disease with an ankle-brachial index of \<0.50 or with incompressible vessels;
* Acute deep venous thrombosis (DVT) within 3 months of consent;
* History of stroke within the last 6 months;
* Flow-limiting venous outflow obstruction central to the intended target sites;
* Insufficient inflow through the treatment vein upon manual augmentation;
* Chronic, diffuse, post-thrombotic femoropopliteal vein disease that, in the Investigator's opinion, would preclude venous valve formation or would inhibit flow through the treatment sites;
* Chronic renal insufficiency with creatinine level of ≥2mg/dL;
* Hemoglobin level \<9.0 mg/dL;
* Platelet count \<50,000 or \>1,000,000 per mm3;
* Total white blood cell count \<3,000/mm3;
* Pregnant or lactating female; positive pregnancy test, women of childbearing potential must be tested;
* Non-ambulatory patients;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No